The Uttam Hindu
Home > Celltrion
Celltrion gets interchangeability approval for biosimilar of Humira in US

Celltrion gets interchangeability approval for biosimilar of Humira in US

by The Uttam Hindu |2025-04-14 08:41:40
Celltrion targets $3.46 bn in sales this year on biosimilars

Celltrion targets $3.46 bn in sales this year on biosimilars

by The Uttam Hindu |2025-03-18 10:22:45
Celltrion targets $3.46 bn in sales this year on biosimilars

Celltrion targets $3.46 bn in sales this year on biosimilars

by The Uttam Hindu |2025-03-18 04:52:28
Celltrion launches autoimmune disease treatment in US

Celltrion launches autoimmune disease treatment in US

by The Uttam Hindu |2025-03-13 09:32:28
S.Korean drugmaker Celltrion gets USFDA approval for allergic asthma biosimilar

S.Korean drugmaker Celltrion gets USFDA approval for allergic asthma biosimilar

by The Uttam Hindu |2025-03-10 08:26:48
Celltrions autoimmune disease treatment gets approval in Europe

Celltrion's autoimmune disease treatment gets approval in Europe

by The Uttam Hindu |2025-02-24 05:38:22
Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment

Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment

by The Uttam Hindu |2025-01-31 09:17:54
Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment

Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment

by The Uttam Hindu |2025-01-31 07:49:33
Celltrions autoimmune disease treatment hits 5 major European countries

Celltrion's autoimmune disease treatment hits 5 major European countries

by The Uttam Hindu |2025-01-23 06:36:21
S. Korea fines pharma giant Celltrion for unfair business practices

S. Korea fines pharma giant Celltrion for unfair business practices

by The Uttam Hindu |2024-12-03 07:51:20
S. Korean drugmaker Celltrion to buy back its shares for 4th time in 2024

S. Korean drugmaker Celltrion to buy back its shares for 4th time in 2024

by Kajal Luthra |2024-10-25 06:04:19
X